ClinicalTrials.gg
CompletedNCT02148120Updated Mar 29, 2017

A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThaler

A Phase 2 interventional study of Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg and Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg in Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 3 sites in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-03-29.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing beclomethasone in Asthma — none open to participants now, none under way, none of them phase 3. Beclomethasone · Asthma.

Enrollment
21st of 40
60 · median 67
Started
2014
with 2 others
Phase 2
5 of 40
none open now
Registered
28th of 40
by date
Lead sponsor
12 of 40
Chiesi Farmaceutici S.p.A.

Among the 40 studies testing beclomethasone in Asthma, this one is the 21st largest by enrollment, is one of 3 that started in 2014, is one of 5 in phase 2, and was the 28th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing beclomethasone in Asthma is open now. The open studies under Asthma, anywhere →

About beclomethasone

Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing beclomethasone in Asthma as a file.
02

Study summary

The aim of the study is to demonstrate the non-inferiority in terms of acute bronchodilator effect between a single dose of CHF 1535 NEXThaler 200/6 µg and a single dose of CHF 1535 NEXThaler 100/6 µg at two dose levels in partially controlled and uncontrolled asthmatic patients.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient's written obtained prior to any study-related procedures.
  • Male or female aged between 18 and 65 years inclusive;
  • Evidence for "partially controlled" or "uncontrolled" asthma;
  • Medium daily dose of previous inhaled (ICS) treatment;
  • between 60% and 85% of the predicted normal values;
  • A documented positive response to the reversibility test;
  • Non-smokers or ex-smokers;
  • A cooperative attitude and ability to be trained in the proper use of a DPI.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women and all women physiologically capable of becoming pregnant not willing to use at least one acceptable method of .
  • Significant seasonal variation in asthma occurring or expected to occur during study participation;
  • History of near fatal asthma, brittle asthma, accident and Emergency treatment or hospitalisation for asthma exacerbation in Intensive Care Unit within 1 year before screening;
  • Occurrence of asthma exacerbations or respiratory tract infections in the 4 weeks preceding the screening;
  • Diagnosis of ;
  • History of cystic fibrosis, bronchiectasis or alpha-1 antitrypsin deficiency;
  • Diagnosis of restrictive lung disease;
  • Patients treated with oral or parenteral in the previous 8 weeks;
  • Intolerance or to treatment with beta2-agonists and/or inhaled corticosteroids;
  • Allergy, sensitivity or intolerance to study drugs or ;
  • Patients who received any drug within the last 8 weeks before the screening;
  • Patients taking any of the non-permitted concomitant medication;
  • Subjects unlikely to comply with the study protocol;
  • Any abnormal value or physical finding at screening;
  • Significant medical history;
  • Abnormal and clinically significant 12-lead ;
  • Patients with low compliance of QVAR intake.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    CHF1535 NEXThaler 100/6, 1 puff

    Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg

    Drug: Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg

  • Active comparator
    CHF1535 NEXThaler 100/6 µg, 4 puffs

    Beclometasone Dipropionate 400 µg + Formoterol Fumarate 24 µg

    Drug: Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg

  • Experimental
    CHF1535 NEXThaler 200/6 µg, 1 puff

    Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg

    Drug: Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg

  • Experimental
    CHF1535 NEXThaler 200/6 µg, 4 puffs

    Beclometasone Dipropionate 800 µg + Formoterol Fumarate 24 µg

    Drug: Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg

  • Placebo comparator
    Placebo NEXThaler

    Placebo

    Drug: Placebo

Interventions

  • DrugBeclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg

    Drug page: Beclomethasone

    Also known as: Foster NEXThaler

  • DrugBeclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg

    Drug page: Beclomethasone

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. FEV1 Area under the curve

    FEV1= Forced expiratory volume in the first second of expiration

    Time frame: until 12 h post dose

Secondary outcomes

  1. FEV1 peak

    Maximum FEV1 value

    Time frame: until 12 h post dose

  2. FVC area under the curve

    FVC = Forced Vital Capacity

    Time frame: until 12 h post dose

  3. FVC peak

    Maximum FVC

    Time frame: until 12 h post dose

  4. Adverse events

    from the signature of the informed consent until the end of the study, the total duration depends on the duration of the run-in and wash-out periods.

    Time frame: over a period of 5 to 14 weeks

07

Study locations

3 sites
  • Hammersmith Medicines Research
    London, NW10 7EW, United Kingdom
  • Respiratory Clinical Trials, Hearth Lung Centre
    London, W1G 8HU, United Kingdom
  • Medicines Evaluation Unit
    Manchester, M23 9QZ, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2014
First posted
May 28, 2014
Start
Apr 2014
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Last update
Mar 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02148120
Responsible party
Sponsor
First posted
May 28, 2014
Start date
Apr 2014
Primary completion
Oct 2014
Completion
Oct 2014
Last update
Mar 29, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beclomethasone

Start the discussion